Top-News

Altimmune Aktie News

Aktie
WKN:  A2N5Z6 ISIN:  US02155H2004 US-Symbol:  ALT Branche:  Biotechnologie Land:  USA
4,477 €
-0,108 €
-2,36%
07:30:22 Uhr
Depot/Watchlist
Marktkapitalisierung *
255,01 Mio. €
Streubesitz
63,02%
KGV
-5,42
Dividende
54,21 €
Dividendenrendite
1.227,54%
Index-Zuordnung
-

Altimmune News

28.11.25 - wallstreetONLINE Redaktion
Wer macht das Rennen?: Milliarden-Jackpot Adipositas: Amgen & Roche sagen Novo & Lilly den Kampf an!
Novo Nordisk und Eli Lilly waren Vorreiter bei Abnehmmitteln. Beiden wurde eine große Zukunft vorhergesagt. Doch die Konkurrenz ist größer geworden und nur Lilly konnte liefern. ...
07.10.25 - PR Newswire
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
06.10.25 - PR Newswire
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Altimmune, Inc.(ALT) Shareholders
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Altimmune, Inc.(ALT) Shareholders PR Newswire
03.10.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT PR Newswire
03.10.25 - PR Newswire
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune PR Newswire
02.10.25 - PR Newswire
ALT Deadline: ALT Investors with Losses in Excess of $50K Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit
ALT Deadline: ALT Investors with Losses in Excess of $50K Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit PR Newswire
02.10.25 - PR Newswire
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
01.10.25 - PR Newswire
Investors in Altimmune, Inc. Should Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT
Investors in Altimmune, Inc. Should Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights - ALT PR Newswire
01.10.25 - PR Newswire
Altimmune, Inc. (NASDAQ: ALT) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit
Altimmune, Inc. (NASDAQ: ALT) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit PR Newswire
30.09.25 - PR Newswire
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
29.09.25 - PR Newswire
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit PR Newswire
29.09.25 - PR Newswire
Shareholders that lost money on Altimmune, Inc.(ALT) should contact The Gross Law Firm about pending Class Action - ALT
Shareholders that lost money on Altimmune, Inc.(ALT) should contact The Gross Law Firm about pending Class Action - ALT PR Newswire
26.09.25 - PR Newswire
Shareholders that lost money on Altimmune, Inc.(ALT) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
Shareholders that lost money on Altimmune, Inc.(ALT) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More PR Newswire
25.09.25 - PR Newswire
ALTIMMUNE (NASDAQ: ALT) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action by October 6, 2025
ALTIMMUNE (NASDAQ: ALT) CLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action by October 6, 2025 ...
25.09.25 - PR Newswire
Investors in Altimmune, Inc. Should Contact The Gross Law Firm Before October 6, 2025 to Discuss Your Rights - ALT
Investors in Altimmune, Inc. Should Contact The Gross Law Firm Before October 6, 2025 to Discuss Your Rights - ALT PR Newswire
24.09.25 - PR Newswire
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune PR Newswire
23.09.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT PR Newswire
22.09.25 - PR Newswire
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit PR Newswire
22.09.25 - PR Newswire
The Gross Law Firm Reminds Altimmune, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 6, 2025 - ALT
The Gross Law Firm Reminds Altimmune, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 6, 2025 - ALT PR Newswire
22.09.25 - PR Newswire
INVESTOR ALERT: Berger Montague Advises Altimmune, Inc. (NASDAQ: ALT) Investors to Inquire About a Securities Fraud Class Action by October 6, 2025
INVESTOR ALERT: Berger Montague Advises Altimmune, Inc. (NASDAQ: ALT) Investors to Inquire About a Securities Fraud Class Action by October 6, 2025 PR Newswire

Newssuche

Videos

newspaper
02.12.25 +8,18%
Technical Trading: DAX Long dienstags
DAX Long Typ: Turbo Open End WKN: VK2CGA Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »